Avid Bioservices Stock Price, News & Analysis

CDMOP is the preferred stock symbol associated with Avid Bioservices, Inc., a biologics-focused contract development and manufacturing organization (CDMO) in the pharmaceutical preparation manufacturing industry. While Avid’s common stock has historically traded under the symbol CDMO on Nasdaq, CDMOP represents a related listed security that is tied to the same underlying business. Understanding CDMOP therefore starts with understanding Avid Bioservices’ role as a specialist provider of development and CGMP manufacturing services for biologic drugs.

Avid Bioservices describes itself as a dedicated CDMO focused on the development and CGMP manufacturing of biologics for biotechnology and biopharmaceutical companies. According to the company’s public communications, it offers process development, CGMP clinical and commercial manufacturing services, and related support activities for biologic drug programs. The company notes that it has more than 30 years of experience producing biologics, which underpins its service offering to customers in the life sciences sector.

Underlying business: Avid Bioservices, Inc.

Avid Bioservices states that its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submissions support. For early-stage programs, the company reports that it provides process development activities such as cell line development, upstream and downstream development and optimization, analytical methods development, testing, and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization, as described in multiple Avid news releases.

These activities position Avid within the pharmaceutical preparation manufacturing sector as a partner to biotechnology and biopharmaceutical companies that outsource key parts of their biologics development and manufacturing workflows. Rather than marketing its own therapeutic products in these disclosures, Avid emphasizes its role as a service provider to other drug developers.

Corporate developments affecting CDMOP and related securities

Avid Bioservices has disclosed a series of corporate transactions that are relevant to investors researching CDMOP and other Avid securities. On November 6, 2024, Avid announced that it had entered into a definitive merger agreement to be acquired by funds managed by GHO Capital Partners LLP and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. Under that agreement, Avid stockholders were to receive $12.50 per share in cash for each share of common stock, subject to customary closing conditions.

Subsequent communications from Avid reported that stockholders approved the transaction at a special meeting held on January 30, 2025. On February 5, 2025, GHO Capital and Ampersand announced the successful closing of the acquisition of Avid Bioservices. In that same February 5, 2025 news release, it was stated that the company’s common stock had ceased trading and would be delisted from Nasdaq. These events mean that Avid transitioned from a publicly traded company to a privately held business owned by GHO Capital and Ampersand.

Impact of merger and capital structure actions

In connection with the completed merger, Avid also provided a Notice of Fundamental Change and Make-Whole Fundamental Change to holders of its 7.00% Convertible Senior Notes due 2029. The company explained that the closing of the merger constituted a Fundamental Change and a Make-Whole Fundamental Change under the applicable indenture. Holders were given the right to require the company to repurchase their notes for cash at 100% of principal plus accrued and unpaid interest on a specified repurchase date, or to convert their notes during a defined Make-Whole Fundamental Change conversion period at an increased conversion rate.

According to Avid’s February 5, 2025 notice, upon consummation of the merger each share of Avid common stock was converted into the right to receive $12.50 in cash, without interest and subject to applicable withholding taxes. The company also stated that, pursuant to a supplemental indenture, the conversion right for each $1,000 principal amount of the notes was changed to a right to convert into cash based on the applicable conversion rate multiplied by the $12.50 per share merger consideration.

Business operations and service scope

Across its news releases, Avid consistently describes its operations as focused on biologics development and CGMP manufacturing. The company highlights process development capabilities, including cell line development and optimization of upstream and downstream processes. It also references analytical methods development, testing, and characterization as part of its offering, along with bulk packaging and release and stability testing for biologic drug substances.

Avid notes that it supports both clinical and commercial manufacturing programs, indicating that its services extend from early-stage development through to later-stage and commercial supply for qualifying customer products. The company also mentions regulatory submissions support, suggesting involvement in documentation and testing activities that support customer regulatory filings for biologic products.

Trading status and historical context

For investors researching CDMOP, it is important to recognize that Avid’s common equity has been taken private as a result of the completed acquisition by GHO Capital and Ampersand. The company has publicly stated that, upon completion of the transaction, its common stock would no longer be listed on any public stock exchange. While the specific treatment of each related security, including preferred stock such as CDMOP, depends on the terms of those securities and the transaction documents, the broader context is that Avid is no longer a standalone public company.

CDMOP therefore represents a security linked to a CDMO business that has transitioned from public to private ownership. Historical trading data, distributions, and corporate actions for CDMOP should be evaluated in light of the merger, the delisting of Avid’s common stock, and any related capital structure changes disclosed in company communications and regulatory filings.

Use cases for investors and researchers

Investors and analysts examining CDMOP may focus on Avid’s historical performance as a CDMO, as reflected in its prior financial results and backlog disclosures. For example, Avid has reported on revenues, backlog, and profitability trends in its quarterly results, and has discussed factors such as manufacturing and process development revenues, gross profit, and operating expenses. It has also described commercial developments such as new business signings, customer mix, and expansion of capabilities.

While these financial metrics are time-sensitive and change from period to period, they provide historical context for understanding the business underlying CDMOP. The company’s own description of its services, experience in biologics manufacturing, and role as a CDMO to biotechnology and biopharmaceutical customers offers additional qualitative insight into the nature of the enterprise associated with this preferred stock symbol.